Sybleu Inc. Purchases Fifty Percent Stake In Patent NEW YORK, July 11, 2023 /PRNewswire/ -- SYBLEU INC. (OTC PINK: SYBE), a biotechnology company focused on therapies for human and animal health, medical devices, and clinical diagnostics, is preparing to begin advancing small molecule drug therapies for animal and human health.
On June 30, 2023 Sybleu entered into a purchase agreement whereby Sybleu purchased from Zander Biologics, Inc. a fifty percent ownership share of certain small molecule compounds with therapeutic applications. In return, Zander received a 10% Promissory Note in the principal amount of $300,000 due and payable June 30, 2025. Zander is also entitled to receive a contingent payment of 1,000,000 Sybleu common shares in the event documentation recording this transaction is filed with the US Patent and Trademark Office on or prior to July 31, 2023.
These compounds, currently patent protected in the U.S. under patent numbers US 10,472,351 B2 and US 11,377,442 B2, can potentially be developed into therapeutic agents targeting a host of companion animal ailments including cancer and arthritis. Sybleu intends to implement its strategy of synergizing its assets by applying its in-licensed AI/ML (Artificial Intelligence/Machine Learning) engine to further develop the purchased small molecule compounds.
https://www.prnewswire.com/news-releases/sybleu-inc-purchases-fifty-percent-stake-in-patent-protected-small-molecule-therapeutic-compounds-anticipates-synergy-with-recently-in-licensed-aiml-engine-301872346.html